Skip to main content
Advertisement
Advertisement

NTLA

NTLA logo

Intellia Therapeutics, Inc

11.74
USD
Sponsored
+0.31
+2.76%
Oct 15, 13:45 UTC -4
Open

NTLA Earnings Reports

Positive Surprise Ratio

NTLA beat 24 of 42 last estimates.

57%

Next Report

Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.67M
/
-$0.81
Implied change from Q2 26 (Revenue/ EPS)
+39.32%
/
+1.25%
Implied change from Q3 25 (Revenue/ EPS)
-22.58%
/
-11.96%

Intellia Therapeutics, Inc earnings per share and revenue

On Aug 06, 2026, NTLA reported earnings of -0.80 USD per share (EPS) for Q2 26, beating the estimate of -0.81 USD, resulting in a 1.86% surprise. Revenue reached 7.66 million, compared to an expected 14.18 million, with a -46.00% difference. The market reacted with a +2.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 10.67 million USD, implying an increase of 1.25% EPS, and increase of 39.32% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Oct 12, 2026 For Q3 26
Estimate
-$0.61
Actual
$4.73
Surprise
+871.74%
FAQ
For Q2 2026, Intellia Therapeutics, Inc reported EPS of -$0.80, beating estimates by 1.86%, and revenue of $7.66M, -46% below expectations.
The stock price moved up 2.46%, changed from $10.97 before the earnings release to $11.24 the day after.
The next earning report is scheduled for Nov 05, 2026.
Based on 13 analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.81 and revenue of $10.67M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement